Ilaria Portarena

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2026

Stage-dependent performance and molecular subtype-specific relapse patterns on same-session [18F]FDG PET/contrast-enhanced CT in breast cancer.

Stage-dependent performance and molecular subtype-specific relapse patterns on same-session [18F]FDG PET/contrast-enhanced CT in breast cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 14, 2026

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 23, 2025

Post-Operative Complications Do Not Influence Time to Adjuvant Treatment in Breast Cancer Patients Undergoing Implant-Based Reconstructions: Pre-Pectoral Versus Sub-Pectoral.

Post-Operative Complications Do Not Influence Time to Adjuvant Treatment in Breast Cancer Patients Undergoing Implant-Based Reconstructions: Pre-Pectoral Versus Sub-Pectoral.

Journal: Cancers

Published: November 11, 2025

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Journal: The oncologist

Published: June 13, 2025

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III.

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III.

Journal: Current oncology (Toronto, Ont.)

Published: December 23, 2024

Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study.

Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study.

Journal: The breast journal

Published: November 25, 2024

Sacituzumab govitecan in the second line treatment in a patient with triple-negative breast cancer with extensive locoregional recurrence.

Sacituzumab govitecan in the second line treatment in a patient with triple-negative breast cancer with extensive locoregional recurrence.

Journal: Recenti progressi in medicina

Published: November 17, 2024

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Journal: Breast (Edinburgh, Scotland)

Published: October 22, 2024

Implementing the Risk Stratification and Clinical Management of Breast Cancer Families Using Polygenic Risk Score Evaluation: A Pilot Study.

Implementing the Risk Stratification and Clinical Management of Breast Cancer Families Using Polygenic Risk Score Evaluation: A Pilot Study.

Journal: Journal of personalized medicine

Published: August 01, 2024

Radiological and pathological predictors of post-operative upstaging of breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma and lymph-nodes metastasis; a potential algorithm for node surgical de-escalation.

Radiological and pathological predictors of post-operative upstaging of breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma and lymph-nodes metastasis; a potential algorithm for node surgical de-escalation.

Journal: Surgical oncology

Published: September 21, 2023

Socioeconomic Impact of OncotypeDX on Breast Cancer Treatment: Preliminary Results.

Socioeconomic Impact of OncotypeDX on Breast Cancer Treatment: Preliminary Results.

Journal: In vivo (Athens, Greece)

Published: July 16, 2023

Showing 1-12 of 45

Last Updated: 09/26/2026